Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05122559 · ClinicalTrials.gov registry record · Phase 2
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
A Phase 2 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive, sponsored by Emmanuelle Waubant, MD PhD.
- Active
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
- 1
- Study location
NCT05122559 is a Phase 2 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive that is active but no longer recruiting, run by Emmanuelle Waubant, MD PhD. The registered enrollment target is 98 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05122559, a Phase 2 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive, is active but no longer recruiting, sponsored by Emmanuelle Waubant, MD PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG N-acetyl cysteine
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05122559
The ClinicalTrials.gov registry entry for NCT05122559 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (83% lower). The listed sponsor is Emmanuelle Waubant, MD PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05122559 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05122559 about?
NCT05122559 is a clinical study titled "Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis". This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
What is the current status of trial NCT05122559?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2022-02-16. Estimated completion is 2027-02.
What conditions does trial NCT05122559 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive.
What interventions are being tested in trial NCT05122559?
The interventions under investigation include: Placebo (DRUG), N-acetyl cysteine (DRUG).
Who is sponsoring clinical trial NCT05122559?
This trial is sponsored by Emmanuelle Waubant, MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05122559 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Explore more on PlainTrial
Multiple Sclerosis
All registered trials for this condition
Multiple Sclerosis, Secondary Progressive
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.